Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles (Q40941167)
scientific article published on August 1999
Language:
Current Data About Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
(P31) (Q13442814)
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

(P304) 551-560
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

(P407) (Q1860)

(P433) 2
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

(P478) 290
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

(P577) Sunday, August 1, 1999
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

(P921) (Q118125759)
(P887)

(P1433) (Q1500272)
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

(P1476) "Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles" (language: en)
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

(P2093) Chan CC
(P1545) 1
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Boyce S
(P1545) 2
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Brideau C
(P1545) 3
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Charleson S
(P1545) 4
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Cromlish W
(P1545) 5
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Ethier D
(P1545) 6
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Evans J
(P1545) 7
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Ford-Hutchinson AW
(P1545) 8
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Forrest MJ
(P1545) 9
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Gauthier JY
(P1545) 10
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Gordon R
(P1545) 11
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Gresser M
(P1545) 12
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Guay J
(P1545) 13
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Kargman S
(P1545) 14
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Kennedy B
(P1545) 15
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Leblanc Y
(P1545) 16
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Leger S
(P1545) 17
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Mancini J
(P1545) 18
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

O'Neill GP
(P1545) 19
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Ouellet M
(P1545) 20
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Patrick D
(P1545) 21
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Percival MD
(P1545) 22
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Perrier H
(P1545) 23
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Prasit P
(P1545) 24
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

Rodger I
(P1545) 25
(P248)
(P698) 10411562
(P813) Monday, September 25, 2017

other details
description scientific article published on August 1999

External Links
(P698) 10411562